Agios Pharmaceuticals (FRA:8AP) Inventories, Finished Goods: €3.39 Mil (As of Mar. 2026)


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
49 GF Score
Price €38.00
GF Value €74.76
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Inventories, Finished Goods?

Agios Pharmaceuticals FRA:8AP +18.01% 49 Inventories, Finished Goods is €3.39 Mil as of Mar. 2026. GuruFocus rates FRA:8AP with a GF Score™ of 49/100 and a GF Value™ of €74.76. The stock has 5 warning signs investors should review.

Agios Pharmaceuticals's quarterly finished goods stayed the same from Sep. 2025 (€2.20 Mil) to Dec. 2025 (€2.20 Mil) but then increased from Dec. 2025 (€2.20 Mil) to Mar. 2026 (€3.39 Mil).

Agios Pharmaceuticals's annual finished goods increased from Dec. 2023 (€1.34 Mil) to Dec. 2024 (€2.88 Mil) but then declined from Dec. 2024 (€2.88 Mil) to Dec. 2025 (€2.20 Mil).

Agios Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Inventories, Finished Goods Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.89 1.34 2.88 2.20

Agios Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.72 3.08 2.20 2.20 3.39
FRA:8AP
49GF Score
Agios Pharmaceuticals Inc FRA:8AP
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €3.39 Mil mean?
Agios Pharmaceuticals (FRA:8AP) has a Inventories, Finished Goods of €3.39 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Inventories, Finished Goods too high?
Agios Pharmaceuticals' current Inventories, Finished Goods is €3.39 Mil. Overall, Agios Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Inventories, Finished Goods compare to ABCL and KOD?
Agios Pharmaceuticals' Inventories, Finished Goods of €3.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Inventories, Finished Goods is €3.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (FRA:8AP) has a current Inventories, Finished Goods of €3.39 Mil. The stock's GF Value™ is €74.76, compared to a current price of €38.00 — trading 49.2% below its estimated fair value. The current Inventories, Finished Goods is €3.39 Mil. Agios Pharmaceuticals' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Inventories, Finished Goods is €3.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €38.00 is trading 49.2% below its estimated GF Value™ of €74.76.

Key valuation signals for FRA:8AP:

  • Inventories, Finished Goods: €3.39 Mil
  • GF Value™: €74.76 vs. price of €38.00 (49.2% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
49GF Score

Get the complete analysis for FRA:8AP

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.00
Price
€74.76
GF Value